Form 4: Director Kabeer Aziz Acquires AN2 Therapeutics Stock

AN2 Therapeutics Director Kabeer Aziz acquired 11,560 shares of common stock on January 12, 2026, as part of his non-employee director compensation.

Summary

• Kabeer Aziz, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 11,560 shares of common stock.
• The transaction occurred on January 12, 2026.
• These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy and vested immediately.
• Following this transaction, Kabeer Aziz directly beneficially owns 52,479 shares of common stock.
• He also indirectly beneficially owns 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P. and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P., where he may be deemed to share voting and dispositive power.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as compensation, generally indicates alignment of interests and confidence in the company's future, contributing to a moderately positive sentiment. The zero-cost acquisition means no cash outflow from the director, but it still increases their stake.

Positives

• Director Kabeer Aziz increased his direct beneficial ownership in the company by 11,560 shares, aligning his interests with shareholders.
• The shares were issued as compensation, indicating a non-cash expense for the company for director services.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all industries, and does not provide specific industry-related context beyond the company's name, AN2 Therapeutics, Inc., which operates in the biotechnology/pharmaceutical sector.

Corporate Governance

Related Party Transactions

• Kabeer Aziz, as a Director and Secretary of Adjuvant Capital Management, L.L.C. (AC MGMT), is associated with entities (Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.) that indirectly hold a significant number of AN2 Therapeutics shares. This represents a related party interest in the company's stock.

Stakeholder Impact

• Shareholders: Increased director ownership can be seen positively as it aligns management interests with shareholder value.
• Company: Utilizing stock for director compensation can conserve cash.

Key Dates

Recommendation

This Form 4 filing details a routine compensation-related stock acquisition by a director. While it shows alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard insider transaction that typically has minimal impact on the investment thesis.

Keywords

AN2 Therapeutics, ANTX, Kabeer Aziz, Form 4, Insider Trading, Director Compensation, Stock Acquisition, Beneficial Ownership